Transenterix Inc. (TRXC): Anthony C. J. Fernando , Chief Technology Officer of Transenterix Inc. purchased 27,000 shares on Jun 14, 2016. The Insider buying transaction was reported by the company on Jun 15, 2016 to the Securities and Exchange Commission. The shares were purchased at $1.46 per share for a total value of $39,420.00 , the company said in a SEC Form 4 Filing.
Other Insider transactions have been reported by the company according to SEC Form 4, on Nov 18, 2015, Andrea Biffi (director) purchased 25,000 shares at $2.82 per share price.On Nov 16, 2015, Willam N Kelley (director) purchased 20,000 shares at $2.80 per share price.Also, On Nov 12, 2015, Joseph P Slattery (CFO) purchased 15,000 shares at $2.77 per share price.
Shares of Transenterix Inc (TRXC) ended Tuesday, Jun 14, 2016 session in red amid volatile trading. The shares closed down -0.05 points or -3.45% at $1.4 with 4,39,429 shares getting traded. Post opening the session at $1.42, the shares hit an intraday low of $1.39 and an intraday high of $1.47 and the price vacillated in this range throughout the day. The company has a market cap of $161 M and the number of outstanding shares has been calculated to be 11,47,75,850 shares. The 52-week high of Transenterix Inc is $6.1 and the 52-week low is $1.28.
Company has been under the radar of several Street Analysts.Transenterix Inc is Downgraded by Lake Street to Hold and the brokerage firm has set the Price Target at $2. Earlier the firm had a rating of Buy on the company shares. The Rating was issued on May 11, 2016.Transenterix Inc is Reiterated by Lake Street to Buy while Lowering the Price Target of the company shares to $ 2 from a previous price target of $7 . The Rating was issued on Apr 21, 2016.
TransEnterix Inc. is a medical device company focused on the development and commercialization of a robotic assisted surgical system called the SurgiBot System (the SurgiBot System). The Company’s SurgiBot System is designed to utilize flexible instruments through articulating channels controlled directly by the surgeon with robotic assistance while the surgeon remains patientside within the sterile field. It has commercialized the SPIDER Surgical System (the SPIDER System) a manual laparoscopic system in the United States Europe and the Middle East. The SPIDER System utilizes flexible instruments and articulating channels that are controlled directly by the surgeon allowing for multiple instruments to be introduced through a single site. It also offers Flex Ligating Shears (FLS) which is an energy device used with the existing SPIDER Surgical System. The FLS device is designed to deliver controlled energy to ligate and divide tissue.